Treatment of cancer with oncolytic viruses

Abdullayev Hüseyn Aydın

huseyn.abdullayev.2000@bk.ru

Republic of Azerbaijan, Sumgait city. AZ5005

Abstract

The battle against cancer continues to evolve, with oncolytic viruses emerging as a groundbreaking and promising avenue for innovative treatment. This paper provides a comprehensive overview of oncolytic viruses, a unique class engineered to selectively infect and destroy cancer cells, eliciting an immune response against tumors. Beginning with a historical perspective, the narrative explores the mechanisms of action, types of oncolytic viruses, and notable clinical successes, including the FDA approval of a melanoma therapy.

Keywords

Oncolytic viruses Cancer treatment Innovative therapy Targeted therapy Genetic engineering Immune response ,Selectivity Tumor-specific antigens Mechanism of action Clinical trials

1. Main text

Oncolytic Viruses: A Revolutionary Approach in Cancer Treatment In the fight against cancer, researchers and scientists are constantly searching for innovative therapies that can effectively eradicate the disease. One such groundbreaking advancement is the use of oncolytic viruses – a unique class of viruses that show promising potential in cancer treatment. By leveraging the properties of these viruses, scientists aim to develop targeted therapies that specifically attack cancer cells while leaving healthy cells unharmed. Oncolytic viruses are engineered to selectively infect and destroy cancer cells, inducing the immune system to mount a response against the tumor. The concept of utilizing viruses as a weapon against cancer dates back to the early 20th century, when anecdotal evidence of cancer remission after viral infections began to emerge. Decades of research have since paved the way for the development of sophisticated oncolytic viruses that can effectively target a wide range of cancer types. One major advantage of oncolytic viruses is their ability to specifically recognize and enter cancer cells. Unlike traditional cancer treatments like chemotherapy or radiation, which can harm healthy tissues, oncolytic viruses can be designed to selectively infect tumor cells based on specific genetic alterations commonly found in cancerous cells. This specificity allows for targeted therapy, minimizing damage to healthy tissues and reducing side effects. Moreover, oncolytic viruses have the ability to replicate within cancer cells, leading to the destruction of tumor tissue. These viruses can be

engineered to release factors that directly kill cancer cells or trigger an immune response, enabling the immune system to recognize and eliminate cancer cells throughout the body. By stimulating the immune system, oncolytic viruses have the potential to generate a systemic anti-tumor response, preventing the recurrence of cancer and improving long-term outcomes. One example of an oncolytic virus that has shown remarkable promise is the genetically modified herpes simplex virus type-1 (HSV-1). In a clinical trial conducted on patients with metastatic melanoma, the HSV-1 oncolytic virus demonstrated impressive tumor regression rates, with durable responses observed in a subset of patients. The success of this trial has fueled further research and development of oncolytic viruses across various cancer types. However, challenges still remain in the utilization of oncolytic viruses for cancer treatment. One obstacle is the body's natural defense mechanisms, which may neutralize or limit the effectiveness of the virus. Researchers are actively pursuing strategies to enhance viral delivery and replication within tumors, as well as identify ways to overcome the immune system's response to the virus. Another aspect that requires attention is the optimization of viral engineering to improve safety profiles. While oncolytic viruses are designed to target cancer cells, there is always a risk of unintended side effects or off-target effects. Scientists must ensure that the viruses possess sufficient selectivity towards cancer cells to avoid harming healthy tissues. In conclusion, oncolytic viruses represent a groundbreaking approach in cancer treatment, offering the potential for targeted therapy and durable responses. As research on these viruses continues to advance, we can anticipate further advancements in treatment options for patients battling various types of cancer. While challenges remain, the immense potential of oncolytic viruses to revolutionize cancer therapy makes them an exciting area of scientific exploration with the power to transform the lives of countless individuals.

Cancer, one of the leading causes of death worldwide, continues to pose a significant challenge to modern medicine. Traditional treatments like chemotherapy and radiation therapy, while effective to some extent, often cause severe side effects and may not provide a cure for certain types of cancer. In recent years, a promising and innovative approach to cancer therapy has emerged – oncolytic viruses. These viruses, which selectively target and destroy cancer cells while sparing healthy ones, are paving the way for a new era in cancer treatment.

Understanding Oncolytic Viruses

Oncolytic viruses are a diverse group of viruses that have been genetically modified or naturally evolved to specifically infect and kill cancer cells. Unlike normal cells, cancer cells often have weakened antiviral defenses, making them susceptible to viral infections. Oncolytic viruses exploit these vulnerabilities to selectively replicate within cancer cells, causing their destruction. Furthermore, the immune response

triggered by the virus helps in attacking remaining cancer cells throughout the body. (Page :1)

Mechanism of Action

Upon infection of cancer cells, oncolytic viruses undergo replication and assembly, ultimately leading to the lysis (breaking down) of the cancer cell. This process releases new viral particles, which can infect neighboring cancer cells, amplifying the therapeutic effect. Additionally, the destruction of cancer cells releases tumor-specific antigens, stimulating the immune system to recognize and attack other cancer cells, including those that are distant from the original site.

Types of Oncolytic Viruses

Several types of viruses have shown promise as oncolytic agents. Examples include adenoviruses, herpes simplex viruses, reoviruses, and vesicular stomatitis viruses. Each of these viruses has unique properties that make them suitable candidates for specific types of cancer.

Clinical Success and Challenges

Oncolytic viruses have demonstrated remarkable success in preclinical studies and early-phase clinical trials. In 2015, the U.S. Food and Drug Administration (FDA) approved the first oncolytic virus therapy for melanoma. Since then, ongoing research and clinical trials are exploring the potential of these viruses in treating various cancer types, including brain tumors, pancreatic cancer, and breast cancer.

However, challenges remain. The immune system can neutralize the virus before it reaches the tumor site. Moreover, not all cancer types are equally susceptible to oncolytic viruses. Researchers are continuously working to enhance the specificity, efficacy, and safety of oncolytic viruses through genetic engineering and combination therapies with other cancer treatments.(Page:2)

Future Prospects

The field of oncolytic virotherapy holds immense promise. As researchers delve deeper into understanding the complex interactions between viruses, cancer cells, and the immune system, novel oncolytic viruses are being developed. Personalized virotherapies tailored to individual patients based on their genetic makeup and specific cancer profiles are on the horizon.

Furthermore, the synergy between oncolytic viruses and immunotherapies, such as immune checkpoint inhibitors, is being explored. Combining these therapies can potentially enhance the immune response against cancer, leading to more durable and widespread responses. (Page:3)

Conclusion

Oncolytic viruses represent a groundbreaking approach to cancer therapy, offering a targeted and potentially

curative treatment for various types of cancer. As research advances and technology evolves, oncolytic virotherapy is likely to become an integral part of the oncologist's toolkit, offering hope to millions of cancer patients worldwide. Through continued innovation and collaboration, the vision of a world where cancer is effectively controlled and even cured is gradually becoming a reality.

Pictures:

Page:1



Page:2



Page:3



References:

1. **"Oncolytic Viruses: Methods and Protocols"** edited by Chunlai Zuo and Wei Cao
2. **"Oncolytic Viruses"** by Darren Shafren 2017, Molecular Therapy - Oncolytics
3. **Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer** Nancy Y. Villa, Lina S. Franco, Grant McFadden (səh. 95-110) - 2020
4. 4. **Methods for Modification of Therapeutic Viruses** Claudia A. P. Hill, Luca Bau, Robert Carlisle (səh.7-290)-2019
5. **Immunohistochemistry for Tumor-Infiltrating Immune Cells After Oncolytic Virotherapy** Dipongkor Saha, Samuel D. Rabkin (səh.179-190) - September 2019
6. 6.**Generating Primary Models of Human Cancer to Aid in the Development of Clinically Relevant Oncolytic Viruses** Brian A. Keller, Marie-Ève Wedge, Abera Surendran, Carolina S. Ilkow (Səh.271-284)- January 2020